Condition
Carcinoma, Non-Small-Cell Lung|Mesothelioma|Bladder Cancer|Ovarian Cancer|Peritoneal Cancer|Thymoma|Thymus Cancer|Uterine Cervical Cancer
Estimated Enrollment: 24
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: UCCI-EXP-16-01
Study First Received: January 13, 2017
Last Updated: January 13, 2017
Estimated Primary Completion Date: January 2020
Primary Outcome Measures:
Dose-limiting toxicity of the combination of bosutinib and pemetrexed|Maximum tolerated dose of the combination of bosutinib and pemetrexed|Adverse events of the combination of bosutinib and pemetrexed|Anti-tumor response rate|Progression-free survival
Sponsors and Collaborators:
Nagla Karim|University of Cincinnati
Website Link: https://ClinicalTrials.gov/show/NCT03023319
